<DOC>
	<DOCNO>NCT01231685</DOCNO>
	<brief_summary>HIV infection exerts negative impact course HCV infection . Co-infected individual progress rapidly liver fibrosis , cirrhosis ESLD compare infected HCV alone . Some accelerated fibrosis may relate longterm chronic toxicity protease inhibitor base ART . Hypothesis : Switching ritonavir boosted-PI base ART regimen Raltegravir-based regimen reduce rate hepatic fibrosis progression HIV-HCV co-infected patient measure transient elastography ( Fibroscan® ) AST-to-platelet ratio index ( APRI ) .</brief_summary>
	<brief_title>Raltegravir Switch Study Reduce Liver Fibrosis Progression HIV-Hepatitis C Co-infection</brief_title>
	<detailed_description>Primary Objective-To ass switch ritonavir boosted-PI base ART regimen Raltegravir-based regimen reduce rate hepatic fibrosis progression HIV-HCV co-infected patient measure transient elastography ( Fibroscan® ) AST-to-platelet ratio index ( APRI ) 48 week treatment . Secondary Objectives : ( ) To assess safety tolerability switch ritonavir boosted-PI ART regimen raltegravir-based regimen 48 week . ( ii ) To evaluate hepatic function ( liver enzymes ) week 0 , 2 , 4 , 8 , 12 , 24 , 36 , 48 72 post switch . ( iii ) To evaluate effect switch treatment control HIV infection ( measure HIV viral load CD4 ) week 0 , 4 , 8 , 12 , 24 , 36 , 48 , 72 post switch . ( iv ) To evaluate metabolic profile ( e.g , fast lipid profile , glucose insulin ) week 0 , 24 , 48 72 post switch . ( v ) To evaluate inflammatory marker associate liver fibrosis week 0 , 2 , 4 , 8 , 12 , 24 , 36 , 48 72 post switch . Population : Patients select CTN222 ; Canadian National multisite prospective cohort HCV-HIV infected person ( N=978 ) eligible patient follow participate site . All patient recruit cohort adult age 16 year old document HIV infection ( ELISA western blot confirmation ) chronic HCV infection evidence HCV exposure ( e.g . HCV-seropositive ELISA RIBA II EIA confirmation , serologically false negative , HCV RNA+ ) . Study Design : A Randomized Prospective Open label study Sample Size : N = 40 This Phase II study design evaluate safety feasibility switch raltegravir HIV-HCV co-infected patient . As neither duration time require improve fibrosis potential impact switch currently know , trial provide important pilot data estimate true effect size calculate sample size require conduct large definitive study question . It hypothesize switch therapy lead significant reduction fibrosis measure APRI FibroScan® . In study , example , successful HCV treatment use FibroScan® , 34 % reduction fibrosis score observe obtain sustain virologic response 48 week ( e.g. , mean baseline score 10.3 kPa 6.6 kPa 48 week ; s.d.= 5 kPa 1 ) . We propose sample size 20 patient group , would provide approximately 80 % power detect least difference 5 kPa fibrosis score change two group assume similar standard deviation .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>HIV Protease Inhibitors</mesh_term>
	<mesh_term>Raltegravir Potassium</mesh_term>
	<mesh_term>Protease Inhibitors</mesh_term>
	<criteria>1 . 18 year old 2 . Chronic HIVHCV coinfection ( HCV RNA + least 6 month could previous HCV treatment ) . 3 . Receiving ritonavir boost PIbased ART least 6 month . 4 . APRI score ≥ 1.5 ( equivalent liver biopsy score ≥ F2 ) AND/OR Fibroscan &gt; 6.9KPa 5 . HIV viral suppression ( &lt; 50 copies/mL ) least 6 month . 6 . No prior evidence resistance raltegravir coadministered nucleoside backbone . 7 . No prior history virologic failure . 1 . Clinical evidence decompensated liver disease ( e.g. , ascites , esophageal varix , hepatic encephalopathy hepatoma hepatocellular carcinoma ) . 2 . Chronic Hepatitis B infection ( define positive HBsAg Hepatitis B viral load great 10,000 copies/mL ) . 3 . AFP great equal 200 ng/mL screening . 4 . Known suspect Wilson 's disease , alpha1antitrypsin deficiency , celiac disease cause chronic liver disease . 5 . Chronic renal insufficiency ( eGFR &lt; 20 mL/min ) screening . 6 . Pregnancy plan pregnancy ( WOCBP use adequate contraception ) . 7 . Women breastfeed . 8 . Active opportunistic infection ( except oral thrush ) neoplasm ( except Kaposi 's sarcoma , skin cancer , cancer cervix anus , unless know suspected liver metastasis ) . 9 . Patients intend start HCV therapy within treatment phase ( within year follow baseline visit ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Liver fibrosis</keyword>
	<keyword>HIV</keyword>
	<keyword>Hepatitis C Virus</keyword>
	<keyword>Coinfection</keyword>
</DOC>